Diffusion and mathematical modeling of release profiles from nanocarriers

α-bisabolol-loaded lipid-core nanocapsules reduce lipopolysaccharide-induced pulmonary inflammation in mice

“…The interfacial deposition of preformed polymer is one of the most effective methods for the preparation of nanocapsule formulations, particularly to carry lipophilic drugs. [21][22][23][24][25][26]34 Injection of the organic phase into the aqueous phase creates a colloidal suspension solution with a pearly white bluish color. This bluish color is due to the Tyndall effect, which is observed when light is scattered by the fine particles dispersed in water.…”

“…The mechanisms of encapsulation and release of several drugs from nanoparticle-based systems have been extensively studied by our group. 25,[35][36][37][38] Here, the high α-bis loading capacity of LNCs was a consequence of its concomitant use as a core constituent and active ingredient, leading to an apparent solubility in water of ~10 mg mL −1 in the α-bis-LNCs.…”

“…20 Nanocapsules are vesicular systems in which the drug/active principle can be confined in an oily cavity surrounded by a polymeric wall 21 that allows the therapeutic effectiveness to be increased. Thus, nanoencapsulation of drug substances has demonstrated improved stability, 22 controlled release, [21][22][23] improved activity, 24 targeted to a specific organ or tissue, 25 and reduced side effects. 26 Considering the well-established anti-inflammatory properties of α-bis as well as the possibility of improving its delivery and translational prospective, the aim of this study was to evaluate the effectiveness of α-bis-loaded lipid-core nanocapsules (α-bis-LNCs) in a mouse model of acute lung injury (ALI) induced by lipopolysaccharide (LPS).…”

High encapsulation efficiency of sodium alendronate in eudragit S100/HPMC blend microparticles

“…29,30 The Korsmeyer-Peppas model 31 (Equation 4) was used to explain the drug release mechanism. In this equation, ft is the ratio of absolute cumulative amount of the drug released at time t and at infinite time, k is a constant incorporating structural and geometric characteristic of the carrier, and n is the release exponent, indicative of the mechanism of the drug release.…”

“…The first phase can be attributed to the burst effect (kinetic constant α) and the second phase is correlated to the sustained release (kinetic constant β). 29,35 The half-lives of the drug released from MP-F4M were calculated for each burst and sustained phases, being 1 and 182 min, respectively. For MP-K100, the values of the half-lives were 2 and 165 min for the burst and the sustained phases, respectively.…”